Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Freenome, Inc.
Report date July 20, 2026 · Filed July 24, 2026
Section 16 reporting ended · disclosed 2026-07-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-07-20 transaction · row 1
1 source rowRow 1 · 2026-07-20 · Conversion · Acquired 30,000 · Balance 30,000 F1: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. |
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-20 · Conversion · Disposed 30,000 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis.
RayzeBio, Inc.
Report date February 26, 2024 · Filed February 27, 2024
Section 16 reporting ended · disclosed 2024-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy trust | 0 |
Reported balance
After 2024-02-26 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-02-26 · Disposition to issuer · Disposed 1,622,968 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount. F2: Includes 873 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on February 22, 2024. F3: The Song Family Trust dated October 14, 2016, or the Song Trust. Dr. Song is a trustee of the Song Trust, and may be deemed to have voting and investment power over the shares held by the Song Trust. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2032-11-30 | IndirectBy trust | 0 |
Reported balance
After 2024-02-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-26 · Disposition to issuer · Disposed 758,607 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3: The Song Family Trust dated October 14, 2016, or the Song Trust. Dr. Song is a trustee of the Song Trust, and may be deemed to have voting and investment power over the shares held by the Song Trust. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.39 · Expires 2033-08-21 | IndirectBy trust | 0 |
Reported balance
After 2024-02-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-26 · Disposition to issuer · Disposed 114,763 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3: The Song Family Trust dated October 14, 2016, or the Song Trust. Dr. Song is a trustee of the Song Trust, and may be deemed to have voting and investment power over the shares held by the Song Trust. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.72 · Expires 2033-11-16 | IndirectBy trust | 0 |
Reported balance
After 2024-02-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-26 · Disposition to issuer · Disposed 480,000 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3: The Song Family Trust dated October 14, 2016, or the Song Trust. Dr. Song is a trustee of the Song Trust, and may be deemed to have voting and investment power over the shares held by the Song Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount.
F2: Includes 873 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on February 22, 2024.
F3: The Song Family Trust dated October 14, 2016, or the Song Trust. Dr. Song is a trustee of the Song Trust, and may be deemed to have voting and investment power over the shares held by the Song Trust.
F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2026 Filed Jul 24, 2026 20:08 UTC | Freenome, Inc. FRNM · Entity 4644 | ConversionClass B Ordinary Shares · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001602787-26-000004 · form4-07242026_080735.xml · derivative · entry 2 SONG KENNETH · CIK 0001602787 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. F1 · price: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. F1 · derivative.exercise_date: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. F1 · derivative.expiration_date: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. Read SEC document |
| July 20, 2026 Filed Jul 24, 2026 20:08 UTC | Freenome, Inc. FRNM · Entity 4644 | ConversionCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001602787-26-000004 · form4-07242026_080735.xml · nonDerivative · entry 1 SONG KENNETH · CIK 0001602787 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:41 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 480,000 | Not disclosed Strike: $22.72 | Not disclosed |
DisclosureSEC source: 0001415889-24-005500 · form4-02272024_090208.xml · derivative · entry 4 SONG KENNETH · CIK 0001602787 · Director · PRESIDENT AND CHIEF EXECUTIVE 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 0 Underlying: Common Stock · 480,000 shares Expires 2033-11-16 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · ownership.nature: The Song Family Trust dated October 14, 2016, or the Song Trust. Dr. Song is a trustee of the Song Trust, and may be deemed to have voting and investment power over the shares held by the Song Trust. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:41 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 114,763 | Not disclosed Strike: $10.39 | Not disclosed |
DisclosureSEC source: 0001415889-24-005500 · form4-02272024_090208.xml · derivative · entry 3 SONG KENNETH · CIK 0001602787 · Director · PRESIDENT AND CHIEF EXECUTIVE 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 0 Underlying: Common Stock · 114,763 shares Expires 2033-08-21 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · ownership.nature: The Song Family Trust dated October 14, 2016, or the Song Trust. Dr. Song is a trustee of the Song Trust, and may be deemed to have voting and investment power over the shares held by the Song Trust. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:41 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 758,607 | Not disclosed Strike: $3.24 | Not disclosed |
DisclosureSEC source: 0001415889-24-005500 · form4-02272024_090208.xml · derivative · entry 2 SONG KENNETH · CIK 0001602787 · Director · PRESIDENT AND CHIEF EXECUTIVE 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 0 Underlying: Common Stock · 758,607 shares Expires 2032-11-30 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · ownership.nature: The Song Family Trust dated October 14, 2016, or the Song Trust. Dr. Song is a trustee of the Song Trust, and may be deemed to have voting and investment power over the shares held by the Song Trust. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:41 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerCommon Stock | 1,622,968 | $62.50 | $101,435,500.00 |
DisclosureSEC source: 0001415889-24-005500 · form4-02272024_090208.xml · nonDerivative · entry 1 SONG KENNETH · CIK 0001602787 · Director · PRESIDENT AND CHIEF EXECUTIVE 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount. F2 · shares: Includes 873 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on February 22, 2024. F3 · ownership.nature: The Song Family Trust dated October 14, 2016, or the Song Trust. Dr. Song is a trustee of the Song Trust, and may be deemed to have voting and investment power over the shares held by the Song Trust. Read SEC document |
| November 17, 2023 Filed Nov 17, 2023 23:38 UTC | RayzeBio, Inc. RYZB · Entity 93779 | GrantStock Option (right to buy) · Derivative | 480,000 | $0.00 Strike: $22.72 | $0.00 |
DisclosureSEC source: 0001628280-23-039537 · wk-form4_1700264271.xml · derivative · entry 1 SONG KENNETH · CIK 0001602787 · Director · President and Chief Executive 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 480,000 Underlying: Common Stock · 480,000 shares Expires 2033-11-16 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments over the four-year period measured from the date of grant. F2 · ownership.nature: The Song Family Trust dated October 14, 2016, or the Song Trust. Dr. Song is a trustee of the Song Trust, and may be deemed to have voting and investment power over the shares held by the Song Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.